オルカ・セラピューティクス
Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.66 | $0 | -$33M |
| 2026 Q1 | -0.58 | $0 | -$24M |
| 2025 Q4 | -0.54 | $0 | -$23M |
| 2025 Q3 | -0.69 | $0 | -$22M |
| 2025 Q2 | -0.58 | $0 | -$23M |
| 2025 Q1 | -0.50 | $0 | -$21M |
| 2024 Q4 |
| -1.54 |
| $0 |
| -$19M |
| 2024 Q3 | -1.91 | $0 | -$35M |